Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayer Fishman

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
American Journal of Clinical Oncology|January 30, 2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesJames Larkin, Mayer Fishman, Laura Wood, et al.
Cancers|June 12, 2026
Current Clinical Utility of Gene Expression Panels in Primary Cutaneous MelanomaTaylor L Garza, Jae Hwan Choi, Michelle McGee, et al.
Urologic Oncology|June 22, 2015
Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinomaPranav Sharma, Kamran Zargar-Shoshtari, Jamie T Caracciolo, et al.
Cancer Research|September 20, 2006
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patientsNoweeda Mirza, Mayer Fishman, Ingo Fricke, et al.
Cancer Research|February 3, 2016
Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic LesionsJan T Poleszczuk, Kimberly A Luddy, Sotiris Prokopiou, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanomaSteven E Finkelstein, Timothy Carey, Ingo Fricke, et al.
Clinical Genitourinary Cancer|March 7, 2022
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal CancerJonathan Chatzkel, Michael J Schell, Jad Chahoud, et al.
Cancer|December 30, 2020
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findingsAasha I Hoogland, Heather S L Jim, Brian D Gonzalez, et al.
Clinical Genitourinary Cancer|December 30, 2014
Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinomaTimothy Kim, Kamran Zargar-Shoshtari, Jasreman Dhillon, et al.
Molecular Cancer Therapeutics|August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trialGeorge R Simon, Richard M Lush, Jana Gump, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
American Journal of Clinical Oncology|January 30, 2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesJames Larkin, Mayer Fishman, Laura Wood, et al.
Cancers|June 12, 2026
Current Clinical Utility of Gene Expression Panels in Primary Cutaneous MelanomaTaylor L Garza, Jae Hwan Choi, Michelle McGee, et al.
Urologic Oncology|June 22, 2015
Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinomaPranav Sharma, Kamran Zargar-Shoshtari, Jamie T Caracciolo, et al.
Cancer Research|September 20, 2006
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patientsNoweeda Mirza, Mayer Fishman, Ingo Fricke, et al.
Cancer Research|February 3, 2016
Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic LesionsJan T Poleszczuk, Kimberly A Luddy, Sotiris Prokopiou, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanomaSteven E Finkelstein, Timothy Carey, Ingo Fricke, et al.
Clinical Genitourinary Cancer|March 7, 2022
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal CancerJonathan Chatzkel, Michael J Schell, Jad Chahoud, et al.
Cancer|December 30, 2020
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findingsAasha I Hoogland, Heather S L Jim, Brian D Gonzalez, et al.
Clinical Genitourinary Cancer|December 30, 2014
Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinomaTimothy Kim, Kamran Zargar-Shoshtari, Jasreman Dhillon, et al.
Molecular Cancer Therapeutics|August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trialGeorge R Simon, Richard M Lush, Jana Gump, et al.
Pageof 7